News

March 3, 2017March 3, 2017

Genetic Signatures Can Help Predict Likelihood of Complications in Young Crohn’s Patients

News

Specific biological markers in pediatric patients newly diagnosed with Crohn’s disease can help to predict those who will go on to develop disease-related complications, and those will best respond to treatment. The study, “Prediction ... Read more

March 2, 2017

TopiVert Begins Phase 1 Study of Oral TOP1288 as Colitis Treatment

News

The first participant has been dosed in a Phase 1 American study evaluating TopiVert Pharma‘s oral version of TOP1288 as a treatment for ulcerative colitis (UC). The study will assess TOP1288’s ... Read more

March 1, 2017

Corticosteroids, High-Dose Pulmicort Both Effective Therapies for Mild-to-Moderate Crohn’s

News

Treatment with corticosteroids and high-dose Pulmicort (budesonide) are both effective induction therapies for patients with mild-to-moderate Crohn’s disease, though high-dose Asacol (mesalamine) also offers an effective alternative with fewer side effects. ... Read more

February 28, 2017

Medicines Targeting Inflammatory Factor IL-1 May Help Combat IBD, Study Suggests

News

Scientists have discovered a potent inflammatory factor called interleukin (IL)-1 that is released during necroptosis, a type of cell death by suicide often present in inflammatory bowel disease (IBD). The ... Read more

February 27, 2017

Cellceutix’s IBD Therapy Brilacidin Progresses to Highest Dose Group in Phase 2 Trial

News

Cellceutix says the ongoing Phase 2 clinical trial of its lead drug candidate Brilacidin has progressed to its third cohort (highest dose) to induce remission of mild-to-moderate ulcerative colitis, now that the study’s Safety Committee has ... Read more

February 24, 2017

Colectomy Increases Risk of Gallstones in Patients with Ulcerative Colitis, Study Suggests

News

The risk of gallstones increases after patients with ulcerative colitis have undergone a colectomy, according to the results of a Danish study. The study, “Increased Risk of Gallstone Disease Following ... Read more

February 23, 2017

Biosimilar Inflectra Matches Remicade as Crohn’s Treatment, Trial Results Show

News

The biosimilar therapy Inflectra (infliximab CT-P13) is as good a treatment as Remicade (infliximab) for those with moderate-to-severe Crohn’s disease (CD), according to the results of a clinical trial. Pfizer and Celltrion Healthcare, ... Read more

February 22, 2017

Entyvio for IBD Shows Promising Safety Results in Long-term Clinical Trial

News

Takeda Pharmaceuticals recently presented positive five-year results of an eight-year clinical trial (NCT00790933) evaluating the long-term safety of Entyvio (vedolizumab) in patients with active ulcerative colitis and Crohn’s disease, two of the ... Read more

February 20, 2017May 23, 2017

Janssen Reports Positive 2-Year Results for Stelara as Crohn’s Treatment

News

Janssen-Cilag International reported results from its ongoing IM-UNITI long-term extension (LTE) clinical trial assessing the efficacy and safety of subcutaneous (SC) Stelara (ustekinumab) in patients with moderate to severe Crohn’s ... Read more

February 17, 2017

Changes in T-bet Proteins May Predispose Individuals For IBD, Study Says

News

Genetic variations affecting a protein called T-bet may predispose individuals to inflammatory bowel disease (IBD), according to a study. This finding may contribute to the development of novel treatments for ... Read more